Alpha Tau Medical Ltd. Ordinary Shares (DRTS) Stock
Key stats
- Market cap
- $1.30B
- Price / Earnings ratio
- -13.7x
- EPS (TTM)
- -$1.04
- Volume
- Loading
- 52-week high
- $15.79
- 52-week low
- $3.43
Source: third-party data provider, as of November 13, 2026
Compare with DRTS
Recent news

New Strong Sell Stocks for July 7th
New Strong Sell Stocks for July 7th
DRTS

New Strong Sell Stocks for July 2nd
New Strong Sell Stocks for July 2nd
DRTS

Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears
DRTS

Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study
Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study
DRTS
Technical indicators
- RSI 14
- 53.52
- MACD 12/26/9
- -0.03
- EMA 9 of MACD
- -0.17
- MACD histogram
- 0.13
- SMA 50
- $14.11
- Price below SMA 50
- EMA 50
- $13.70
- Price above EMA 50
- SMA 200
- $10.86
- Price above SMA 200
- EMA 200
- $10.75
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

New Strong Sell Stocks for July 7th
New Strong Sell Stocks for July 7th
DRTS

New Strong Sell Stocks for July 2nd
New Strong Sell Stocks for July 2nd
DRTS

Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears
DRTS

Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study
Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study
DRTS

DRTS Stock Rises Overnight: Early US Brain Cancer Trial Results Expected Today
DRTS Stock Rises Overnight: Early US Brain Cancer Trial Results Expected Today
DRTS

DRTS Stock Pops Pre-Market: Retail Hype Soars On Cancer Trial Expansion
DRTS Stock Pops Pre-Market: Retail Hype Soars On Cancer Trial Expansion
DRTS

HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT
HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT
DRTS

New Strong Sell Stocks for January 27th
New Strong Sell Stocks for January 27th
DRTS

New Strong Sell Stocks for January 20th
New Strong Sell Stocks for January 20th
DRTS

OurCrowd Launches $200 Million Global Health Equity Fund in collaboration with the WHO Foundation at the Clinton Global Initiative
OurCrowd Launches $200 Million Global Health Equity Fund in collaboration with the WHO Foundation at the Clinton Global Initiative
DRTS
About Alpha Tau Medical Ltd. Ordinary Shares
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Uzi Sofer | CEO & Chairman | 1970 |
| Mr. Raphi Levy | Chief Financial Officer | 1985 |
| Mr. Amnon Gat | Chief Operations Officer | 1975 |
| Mr. Ronen Segal | Chief Technology Officer | 1973 |
| Ms. Rebecca Becker | Vice President of legal | — |
| Ms. Yael Zeiger | Corporate Controller | 1983 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 53.52
- MACD 12/26/9
- -0.03
- EMA 9 of MACD
- -0.17
- MACD histogram
- 0.13
- SMA 50
- $14.11
- Price below SMA 50
- EMA 50
- $13.70
- Price above EMA 50
- SMA 200
- $10.86
- Price above SMA 200
- EMA 200
- $10.75
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $16.00
- Average
- $22.67
- High
- $30.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +11.5 | -7.3 | +20.5 | +26.8 | +30.1 | -6.7 | +18.4 | +6.8 | -10.0 | +6.8 |



